Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yau-Hung Chen, Ya-Ting Lee, Chi-Chung Wen, Yun-Chen Chen & Yu-Jen Chen. (2014) Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish. OncoTargets and Therapy 7, pages 1169-1175.
Read now
Read now
Yifei Huang, Tan Yang, Wendian Zhang, Yao Lu, Peng Ye, Guang Yang, Bin Li, Shibo Qi, Yong Liu, Xingxing He, Robert J Lee, Chuanrui Xu & Guangya Xiang. (2014) A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo. International Journal of Nanomedicine 9, pages 4581-4595.
Read now
Read now
Hsin-I Chang & Ming-Kung Yeh. (2012) Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. International Journal of Nanomedicine 7, pages 49-60.
Read now
Read now
Yongming Zhang, Aidong Li, Zheng Wang, Zhikai Han, Jie He & Jie Ma. (2008) Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model. Journal of Drug Targeting 16:9, pages 679-687.
Read now
Read now
Articles from other publishers (23)
Sedighe Forouhari, Zahra Beygi, Zahra Mansoori, Sara Hajsharifi, Fatemeh Heshmatnia & Seyed Mohammad Gheibihayat. (2021) Liposomes: Ideal drug delivery systems in breast cancer. Biotechnology and Applied Biochemistry 69:5, pages 1867-1884.
Crossref
Crossref
Yike Jiang, Ziyi Jiang, Mingzhe Wang & Lan Ma. (2022) Current understandings and clinical translation of nanomedicines for breast cancer therapy. Advanced Drug Delivery Reviews 180, pages 114034.
Crossref
Crossref
Nawras Osman, Nikita Devnarain, Calvin A. Omolo, Victoria Fasiku, Yajna Jaglal & Thirumala Govender. (2021) Surface modification of nano‐drug delivery systems for enhancing antibiotic delivery and activity. WIREs Nanomedicine and Nanobiotechnology 14:1.
Crossref
Crossref
Katarzyna Juszkiewicz, Aleksander F. Sikorski & Aleksander Czogalla. (2020) Building Blocks to Design Liposomal Delivery Systems. International Journal of Molecular Sciences 21:24, pages 9559.
Crossref
Crossref
Ram Pada Das, Beena Gobind Singh & Amit Kunwar. (2020) Preparation of a size selective nanocomposite through temperature assisted co-assembly of gelatin and pluronic F127 for passive targeting of doxorubicin. Biomaterials Science 8:15, pages 4251-4265.
Crossref
Crossref
João Nogueira, Sofia F. Soares, Carlos O. Amorim, João S. Amaral, Cláudia Silva, Fátima Martel, Tito Trindade & Ana L. Daniel-da-Silva. (2020) Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy. Molecules 25:2, pages 333.
Crossref
Crossref
Ana Reis-Mendes, Félix Carvalho, Fernando Remião, Emília Sousa, Maria de Lourdes Bastos & Vera Marisa Costa. (2019) The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells. Biomolecules 9:3, pages 98.
Crossref
Crossref
Fu Ou Yang, Nicholas C. Hsu, Sin-Hua Moi, Yin-Che Lu, Chia-Ming Hsieh, King-Jen Chang, Dar-Ren Chen, Chi-Wen Tu, Hwei-Chung Wang & Ming-Feng Hou. (2018) Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study. Asia-Pacific Journal of Clinical Oncology 14:3, pages 198-203.
Crossref
Crossref
Yannan Dou, Kullervo Hynynen & Christine Allen. (2017) To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes. Journal of Controlled Release 249, pages 63-73.
Crossref
Crossref
Yuan-Chin Hsieh, Ta-Chun Cheng, Hsin-Ell Wang, Jia-Je Li, Wen-Wei Lin, Chien-Chiao Huang, Chih-Hung Chuang, Yeng-Tseng Wang, Jaw-Yuan Wang, Steve R. Roffler, Kuo-Hsiang Chuang & Tian-Lu Cheng. (2016) Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. Scientific Reports 6:1.
Crossref
Crossref
Christopher B. Howard, Nicholas Fletcher, Zachary H. Houston, Adrian V. Fuchs, Nathan R. B. Boase, Joshua D. Simpson, Lyndon J. Raftery, Tim Ruder, Martina L. Jones, Christopher J. de Bakker, Stephen M. Mahler & Kristofer J. Thurecht. (2016) Overcoming Instability of Antibody‐Nanomaterial Conjugates: Next Generation Targeted Nanomedicines Using Bispecific Antibodies. Advanced Healthcare Materials 5:16, pages 2055-2068.
Crossref
Crossref
Noha Essam Eldin, Hanan Mohamed Elnahas, Mahmoud Abd-Elghany Mahdy & Tatsuhiro Ishida. (2015) Liposomal Pemetrexed: Formulation, Characterization and <i>in Vitro</i> Cytotoxicity Studies for Effective Management of Malignant Pleural Mesothelioma. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 38:3, pages 461-469.
Crossref
Crossref
Kuo-Hsiang Chuang, Chien-Han Kao, Steve R. Roffler, Ssu-Jung Lu, Ta-Chun Cheng, Yun-Ming Wang, Chih-Hung Chuang, Yuan-Chin Hsieh, Yeng-Tseng Wang, Jaw-Yuan Wang, Kuo-Yi Weng & Tian-Lu Cheng. (2014) Development of an Anti-Methoxy Poly(ethylene glycol) (α-mPEG) Cell-Based Capture System to Measure mPEG and mPEGylated Molecules. Macromolecules 47:19, pages 6880-6888.
Crossref
Crossref
Yosuke Hashimoto, Taro Shimizu, Yu Mima, Amr S. Abu Lila, Tatsuhiro Ishida & Hiroshi Kiwada. (2014) Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs. Toxicology and Applied Pharmacology 277:1, pages 30-38.
Crossref
Crossref
Yuchen Fan & Qiang Zhang. (2013) Development of liposomal formulations: From concept to clinical investigations. Asian Journal of Pharmaceutical Sciences 8:2, pages 81-87.
Crossref
Crossref
Tian-Lu Cheng, Kuo-Hsiang Chuang, Bing-Mae Chen & Steve R. Roffler. (2012) Analytical Measurement of PEGylated Molecules. Bioconjugate Chemistry 23:5, pages 881-899.
Crossref
Crossref
Tommy Tsung Ying Shih. 2011. Interfirm Networks: Theory, Strategy, and Behavior. Interfirm Networks: Theory, Strategy, and Behavior
377
478
.
Kuo-Hsiang Chuang, Hsin-Ell Wang, Fang-Ming Chen, Shey-Cherng Tzou, Chiu-Min Cheng, Ya-Chen Chang, Wei-Lung Tseng, Jentaie Shiea, Shiu-Ru Lin, Jaw-Yuan Wang, Bing-Mae Chen, Steve R. Roffler & Tian-Lu Cheng. (2010) Endocytosis of PEGylated Agents Enhances Cancer Imaging and Anticancer Efficacy. Molecular Cancer Therapeutics 9:6, pages 1903-1912.
Crossref
Crossref
Chien-Hsin Lee, Ting-Chao Chou, Tsann-Long Su, John Yu, Li-En Shao & Alice L Yu. (2009) BO-0742, a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors. Cancer Letters 276:2, pages 204-211.
Crossref
Crossref
Yen-Ju Hsieh, Chih-Hsien Chang, Shu-Pei Huang, Chia-Wen Lin, Meng-Nan Wang, Yu-Tse Wu, Yu-Jen Chen & Tung-Hu Tsai. (2008) Effect of cyclosporin A on the brain regional distribution of doxorubicin in rats. International Journal of Pharmaceutics 350:1-2, pages 265-271.
Crossref
Crossref
R.E. Coleman, L. Biganzoli, P. Canney, L. Dirix, L. Mauriac, P. Chollet, V. Batter, E. Ngalula-Kabanga, C. Dittrich & M. Piccart. (2006) A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). European Journal of Cancer 42:7, pages 882-887.
Crossref
Crossref
Aaron F.H. Lum, Mark A. Borden, Paul A. Dayton, Dustin E. Kruse, Scott I. Simon & Katherine W. Ferrara. (2006) Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles. Journal of Controlled Release 111:1-2, pages 128-134.
Crossref
Crossref
P. Ginopoulos, N. Apostolopoulos, M. Sougleri, N. Koliopoulos, A. Christopoulou, G. Michail, A. Giafis, F. Karvelas, A. Karana, S. Zervoudis & G. Kourounis. (2004) Phase II de l’étude de la doxorubicine pegylatée liposomale en association avec le paclitaxel comme première ligne de traitement du cancer du sein métastatique. Imagerie de la Femme 14:4, pages 287-293.
Crossref
Crossref